Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

59.20
+2.314.06%
Post-market: 59.200.00000.00%18:46 EDT
Volume:6.76M
Turnover:399.40M
Market Cap:4.55B
PE:65.05
High:59.77
Open:57.42
Low:56.56
Close:56.89
52wk High:61.12
52wk Low:26.27
Shares:76.85M
Float Shares:35.24M
Volume Ratio:8.67
T/O Rate:19.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9100
EPS(LYR):0.7500
ROE:13.74%
ROA:8.18%
PB:7.51
PE(LYR):78.93

Loading ...

Kiniksa rises 16.9%

TIPRANKS
·
Apr 28

Stock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance

Stock Track
·
Apr 28

How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story

Simply Wall St.
·
Apr 28

KNSA Earnings: Kiniksa Pharmaceuticals Stock Surges on Strong Q1 Beats

TIPRANKS
·
Apr 28

Kiniksa publishes corporate presentation on ARCALYST growth in recurrent pericarditis market

Reuters
·
Apr 28

Kiniksa reports Q1 EPS 27c, consensus 16c

TIPRANKS
·
Apr 28

Kiniksa raises FY26 revenue view to $930M-$945M from $900M-$920M

TIPRANKS
·
Apr 28

Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate

Benzinga
·
Apr 28

Cardiovascular drugmaker Kiniksa's Q1 net income rises

Reuters
·
Apr 28

Stock Track | Kiniksa Pharmaceuticals Soars 8.67% in Pre-Market on Raised Revenue Guidance and Strong Q1 Results

Stock Track
·
Apr 28

Kiniksa Q1 net income rises to $22.6 million; net product revenue climbs 56% to $214.3 million

Reuters
·
Apr 28

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q1 EPS $0.27

MT Newswires Live
·
Apr 28

BRIEF-Kiniksa Pharmaceuticals Q1 Product Revenue USD 214.266 Million

Reuters
·
Apr 28

Kiniksa Pharmaceuticals Q1 Pretax Profit USD 32.681 Million

THOMSON REUTERS
·
Apr 28

Kiniksa Pharmaceuticals International Plc - Raises 2026 Arcalyst Net Product Revenue Guidance to $930-$945 Mln

THOMSON REUTERS
·
Apr 28

Kiniksa Pharmaceuticals International Plc - Kpl-387 Phase 2 Data Expected 2H 2026; Phase 3 Trial to Initiate by Year-End

THOMSON REUTERS
·
Apr 28

Kiniksa Pharmaceuticals International Plc - Cash and Short-Term Investments $468.1 Mln as of March 31, 2026

THOMSON REUTERS
·
Apr 28

Kiniksa Pharmaceuticals International PLC expected to post earnings of 21 cents a share - Earnings Preview

Reuters
·
Apr 24

Kiniksa Pharmaceuticals schedules first-quarter results conference call and webcast

Reuters
·
Apr 24

Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 16